126 related articles for article (PubMed ID: 9923570)
1. Ciprofibrate treatment in patients with atherogenic lipoprotein phenotype: effects on HDL quality, LDL susceptibility to oxidation and DNA damage.
Raslová K; Dobiásová M; Nagyová A; Fábry R; Rauchová H; Dusinská M
Eur J Clin Pharmacol; 1998; 54(9-10):697-9. PubMed ID: 9923570
[TBL] [Abstract][Full Text] [Related]
2. Effect of ciprofibrate on lipoprotien metabolism and oxidative stress parameters in patients with type 2 diabetes mellitus and atherogenic lipoprotein phenotype.
Raslová K; Nagyová A; Dobiásová M; Ptácková K; Dusinská M
Acta Diabetol; 2000; 37(3):131-4. PubMed ID: 11277313
[TBL] [Abstract][Full Text] [Related]
3. Oxidation resistance of LDL in hypertriglyceridaemic patients treated with ciprofibrate.
Nagyová A; Raslová K; Ginter E
Physiol Res; 1998; 47(3):185-90. PubMed ID: 9803483
[TBL] [Abstract][Full Text] [Related]
4. Action of ciprofibrate in type IIb hyperlipoproteinemia: modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipoprotein-mediated cellular cholesterol efflux.
Guerin M; Le Goff W; Frisdal E; Schneider S; Milosavljevic D; Bruckert E; Chapman MJ
J Clin Endocrinol Metab; 2003 Aug; 88(8):3738-46. PubMed ID: 12915663
[TBL] [Abstract][Full Text] [Related]
5. Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia.
Bruckert E; Dejager S; Chapman MJ
Atherosclerosis; 1993 Apr; 100(1):91-102. PubMed ID: 8318067
[TBL] [Abstract][Full Text] [Related]
6. Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease.
Kontopoulos AG; Athyros VG; Papageorgiou AA; Hatzikonstandinou HA; Mayroudi MC; Boudoulas H
Coron Artery Dis; 1996 Nov; 7(11):843-50. PubMed ID: 8993943
[TBL] [Abstract][Full Text] [Related]
7. The atherogenic role of triglycerides and small, dense low density lipoproteins: impact of ciprofibrate therapy.
Chapman MJ; Bruckert E
Atherosclerosis; 1996 Jul; 124 Suppl():S21-8. PubMed ID: 8831912
[TBL] [Abstract][Full Text] [Related]
8. Dose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia.
Olsson AG; Orö L
Atherosclerosis; 1982 Apr; 42(2-3):229-43. PubMed ID: 6951582
[TBL] [Abstract][Full Text] [Related]
9. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
Aguilar-Salinas CA; Fanghänel-Salmón G; Meza E; Montes J; Gulías-Herrero A; Sánchez L; Monterrubio-Flores EA; González-Valdez H; Gómez Pérez FJ
Metabolism; 2001 Jun; 50(6):729-33. PubMed ID: 11398153
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of ciprofibrate in hyperlipoproteinaemias.
Turpin G; Bruckert E
Atherosclerosis; 1996 Jul; 124 Suppl():S83-7. PubMed ID: 8831920
[TBL] [Abstract][Full Text] [Related]
11. Ciprofibrate effects on carbohydrate and lipid metabolism in type 2 diabetes mellitus subjects.
Hernández-Mijares A; Lluch I; Vizcarra E; Martínez-Triguero ML; Ascaso JF; Carmena R
Nutr Metab Cardiovasc Dis; 2000 Feb; 10(1):1-6. PubMed ID: 10812581
[TBL] [Abstract][Full Text] [Related]
12. Ciprofibrate increases paraoxonase activity in patients with metabolic syndrome.
Paragh G; Seres I; Harangi M; Erdei A; Audikovszky M; Debreczeni L; Kovácsay A; Illyés L; Pados G
Br J Clin Pharmacol; 2006 Jun; 61(6):694-701. PubMed ID: 16722831
[TBL] [Abstract][Full Text] [Related]
13. Paradoxical high-density lipoprotein reduction induced by fenofibrate and ciprofibrate.
Collinson PO; Hjelm CJ; Canepo-Anson R
Ann Clin Biochem; 1996 Mar; 33 ( Pt 2)():159-61. PubMed ID: 8729728
[No Abstract] [Full Text] [Related]
14. Ciprofibrate increases plasma concentration of platelet-derived growth factor AB in patients with advanced atherosclerosis and hyperlipidemia independently of its hypolipidemic effects.
Gajdos M; Mongiellová V; Huttová D; Cibulová L; Krivosíková Z; Spustová V; Dzúrik R
J Cardiovasc Pharmacol; 2001 Nov; 38(5):651-6. PubMed ID: 11602811
[TBL] [Abstract][Full Text] [Related]
15. Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes.
Rizos E; Bairaktari E; Ganotakis E; Tsimihodimos V; Mikhailidis DP; Elisaf M
J Cardiovasc Pharmacol Ther; 2002 Oct; 7(4):219-26. PubMed ID: 12490967
[TBL] [Abstract][Full Text] [Related]
16. Sialic acid-containing components of lipoproteins influence lipoprotein-proteoglycan interactions.
Millar JS; Anber V; Shepherd J; Packard CJ
Atherosclerosis; 1999 Aug; 145(2):253-60. PubMed ID: 10488950
[TBL] [Abstract][Full Text] [Related]
17. Ciprofibrate and lipid profile.
Chandler HA; Batchelor AJ
Lancet; 1994 Jul; 344(8915):128-9. PubMed ID: 7912363
[No Abstract] [Full Text] [Related]
18. Atherogenic lipoprotein profile in families with and without history of early myocardial infarction.
Dobiásová M; Raslová K; Rauchová H; Vohnout B; Ptácková K; Frohlich J
Physiol Res; 2001; 50(1):1-8. PubMed ID: 11300220
[TBL] [Abstract][Full Text] [Related]
19. Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus.
Evans M; Anderson RA; Graham J; Ellis GR; Morris K; Davies S; Jackson SK; Lewis MJ; Frenneaux MP; Rees A
Circulation; 2000 Apr; 101(15):1773-9. PubMed ID: 10769276
[TBL] [Abstract][Full Text] [Related]
20. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B.
Chait A; Brazg RL; Tribble DL; Krauss RM
Am J Med; 1993 Apr; 94(4):350-6. PubMed ID: 8475928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
